BlackRock Fund Advisors’s Ionis Pharmaceuticals IONS Stock Holding History

BlackRock Fund Advisors’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$146M	Buy	3,057,681 +179,570	+6%	+$7.11M	0.03%	892
2016 Q3	$105M	Buy	2,878,111 +77,715	+3%	+$2.43M	0.02%	1017
2016 Q2	$65.2M	Buy	2,800,396 +45,922	+2%	+$1.48M	0.01%	1317
2016 Q1	$112M	Buy	2,754,474 +149,937	+6%	+$6.09M	0.03%	872
2015 Q4	$161M	Sell	2,604,537 -188,458	-7%	-$10.2M	0.04%	611
2015 Q3	$113M	Buy	2,792,995 +175,032	+7%	+$9.06M	0.03%	814
2015 Q2	$151M	Sell	2,617,963 -1,976,136	-43%	-$126M	0.04%	664
2015 Q1	$293M	Buy	4,594,099 +122,641	+3%	+$8.32M	0.07%	306
2014 Q4	$276M	Buy	4,471,458 +351,000	+9%	+$17.3M	0.07%	306
2014 Q3	$160M	Sell	4,120,458 -13,240	-0.3%	-$469K	0.05%	506
2014 Q2	$142M	Sell	4,133,698 -249,389	-6%	-$7.85M	0.04%	612
2014 Q1	$189M	Buy	4,383,087 +175,355	+4%	+$8.5M	0.06%	404
2013 Q4	$168M	Sell	4,207,732 -66,257	-2%	-$2.36M	0.05%	465
2013 Q3	$160M	Buy	4,273,989 +598,421	+16%	+$17.9M	0.05%	425
2013 Q2	$98.8M	Buy	+3,675,568	New	+$78.2M	0.04%	667

Other funds holding IONS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

BlackRock Fund Advisors's IONS Position: Q4 2016 in Review

BlackRock Fund Advisors increased its Ionis Pharmaceuticals (IONS) stake by 6.2% in Q4 2016, buying an estimated $7.11M and bringing the position to 3,057,681 shares worth $146M. The position accounts for 0.03% of the portfolio, ranked #892.

BlackRock Fund Advisors first reported a position in IONS in Q2 2013 and has held it in 15 quarters since. The position peaked at $293M in Q1 2015. 308 funds tracked by Wall St. Rank hold IONS as of Q4 2016.

BlackRock Fund Advisors held 3,057,681 shares of Ionis Pharmaceuticals worth $146M as of Q4 2016.
BlackRock Fund Advisors bought 179,570 Ionis Pharmaceuticals shares in Q4 2016, an estimated $7.11M.
Ionis Pharmaceuticals made up 0.03% of BlackRock Fund Advisors's portfolio in Q4 2016, its #892 holding.
BlackRock Fund Advisors first reported a position in Ionis Pharmaceuticals in Q2 2013 and has held it in 15 quarters since.
BlackRock Fund Advisors's Ionis Pharmaceuticals position peaked at $293M in Q1 2015.
308 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q4 2016.

Based on BlackRock Fund Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.